美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

百济神州

351.93

-2.5400-0.72%

成交量：9.23万

成交额：3,247.04万

市值：401.20亿

市盈率：62.96

高：354.15

开：352.62

低：346.61

收：354.47

52周最高：385.22

52周最低：253.95

股本：1.14亿

流通股本：8,095.27万

量比：0.49

换手率：0.11%

股息：- -

股息率：- -

每股收益(TTM):5.59

每股收益(LYR):2.47

净资产收益率：14.66%

总资产收益率：7.46%

市净率：7.75

市盈率(LYR):142.48

数据加载中...

总览公司新闻资讯公告

康方生物双抗药物获批第三项适应证此前击败百济神州；阿斯利康加入口服减重药“混战”：4500人Ⅲ期临床试验只对标安慰剂｜掘金创新药

每日经济新闻

【特约大V】邓声兴：美伊僵局叠加通胀隐忧，恒指或考验二万五支持

吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！

百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用

港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作将加快RAS赛道开发进展

百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用

中金：维持百济神州(06160)跑赢行业评级目标价266港元

百济神州与Revolution Medicines达成临床开发及区域商业化合作

百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参

每日经济新闻

瞄准“不可成药”靶点！百济神州与Revolution达成合作，布局RAS联合治疗赛道

每日经济新闻

交银国际：百济神州(06160)目标价上调至276港元维持“买入“评级

中金：百济神州“跑赢行业”维持评级目标价升至266港元

百济神州：胰腺癌中KRAS突变率约95%、MTAP缺失率约20%，重叠人群较容易识别

证券日报网

中概股龙头指数盘初上涨0.75%

每日经济新闻

百济神州：百悦达目前由外部CMO供应，各环节均按计划推进

证券日报网

异动解读｜百济神州盘中上涨5.49%，Q2业绩大超预期叠加多家机构上调目标价

百济神州：公司在MCL已形成百悦泽、百悦达及后续联合方案的多层次布局

百济神州：公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者

百济神州：GPC3x4-1BB从进入临床到启动潜在注册性2期研究仅约19个月

百济神州：百悦泽在CLL/SLL新患中的占比已超过50%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/ONC/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":351.93,"timestamp":1791825474540,"preClose":354.47,"halted":0,"volume":92276,"delay":0,"changeRate":-0.007165627556633905,"floatShares":80952700,"shares":113999999,"eps":5.589356,"marketStatus":"交易中","change":-2.54,"latestTime":"10-12 13:18:00 EDT","open":352.615,"high":354.15,"low":346.61,"amount":32470352.93972,"amplitude":0.021271,"askPrice":352.26,"askSize":67,"bidPrice":351.9,"bidSize":60,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":354.47,"preHourTrading":{"tag":"盘前","latestPrice":352.03,"preClose":354.47,"latestTime":"09:27 EDT","volume":10687,"amount":3786015.84129,"timestamp":1791811670034,"change":-2.44,"changeRate":-0.006884,"amplitude":0.010918},"postHourTrading":{"tag":"盘后","latestPrice":352,"preClose":354.47,"latestTime":"19:30 EDT","volume":128814,"amount":45660585.6817,"timestamp":1791588605668,"change":-2.47,"changeRate":-0.006968,"amplitude":0.006968},"volumeRatio":0.491807,"impliedVol":0.3809,"impliedVolPercentile":0.2709},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":80952700,"roa":"7.46%","roe":"14.66%","lyrEps":2.469999,"volumeRatio":0.491807,"shares":113999999,"dividePrice":0,"high":354.15,"amplitude":0.021271,"preClose":354.47,"low":346.61,"week52Low":253.9475,"pbRate":"7.75","psRate":"6.55","week52High":385.22,"institutionHeld":0,"latestPrice":351.93,"committee":-0.055118,"eps":5.589356,"divideRate":0,"volume":92276,"delay":0,"ttmEps":5.589356,"open":352.615,"prevYearClose":303.81,"prevWeekClose":354.47,"prevMonthClose":365.94,"prevQuarterClose":365.94,"fiveDayClose":361.65,"twentyDayClose":353.83,"sixtyDayClose":312.02,"earningDate":1794240000000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2026-11-10","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1794301200000,"name":null,"time":"盘前","dateTimestamp":1794286800000,"actualEps":null},{"market":"US","date":"2026-08-05","symbol":"ONC","fiscalQuarterEnding":"2026/06","expectedEps":1.4,"name":null,"time":"盘前","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":2.05},{"market":"US","date":"2026-05-06","symbol":"ONC","fiscalQuarterEnding":"2026/03","expectedEps":0.73,"name":null,"time":"盘后","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":1.96},{"market":"US","date":"2026-02-26","symbol":"ONC","fiscalQuarterEnding":"2025/12","expectedEps":1.6,"name":null,"time":"盘前","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"pre","actualEps":0.58},{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"盘后","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2963,"buy":0.7037,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7037,"analysts":27,"updateTime":1783915200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-10-09","current":63.043041,"percent":0.661046,"low":-217.585346,"twenty":-67.715123,"median":-23.947641,"eighty":106.735946,"high":609.337035,"avg":45.119883,"sd":205.785765,"marketCap":39810438194},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198},{"date":"2026-01-16","current":546.090088,"twenty":-85.828543,"median":-40.382553,"eighty":-21.503627,"marketCap":37434475537},{"date":"2026-01-23","current":546.929506,"twenty":-85.639801,"median":-40.307741,"eighty":-21.22036,"marketCap":37492017667},{"date":"2026-01-30","current":564.993144,"twenty":-85.550958,"median":-40.153659,"eighty":-20.966373,"marketCap":38730280050},{"date":"2026-02-06","current":560.150346,"twenty":-85.195011,"median":-40.102874,"eighty":-20.825389,"marketCap":38398306221},{"date":"2026-02-13","current":559.214072,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"marketCap":38334124614},{"date":"2026-02-20","current":572.225057,"twenty":-83.309792,"median":-39.846883,"eighty":-20.486836,"marketCap":39226027634},{"date":"2026-02-27","current":124.64483,"twenty":-82.630374,"median":-39.542215,"eighty":-20.122622,"marketCap":35764714896},{"date":"2026-03-06","current":113.265677,"twenty":-81.639564,"median":-39.274234,"eighty":-19.815709,"marketCap":32499660582},{"date":"2026-03-13","current":110.254986,"twenty":-80.905934,"median":-38.936161,"eighty":-19.52935,"marketCap":31635793773},{"date":"2026-03-20","current":109.257937,"twenty":-80.698984,"median":-38.812817,"eighty":-19.378455,"marketCap":31349707731},{"date":"2026-03-27","current":107.028105,"twenty":-78.593786,"median":-38.554628,"eighty":106.63856,"marketCap":30709895147},{"date":"2026-04-02","current":119.197503,"twenty":-77.951,"median":-38.396659,"eighty":109.305857,"marketCap":34201697271},{"date":"2026-04-10","current":121.122038,"twenty":-77.761122,"median":-38.192039,"eighty":109.972102,"marketCap":34753909865},{"date":"2026-04-17","current":123.949552,"twenty":-77.38927,"median":-37.882149,"eighty":113.865362,"marketCap":35565216938},{"date":"2026-04-24","current":115.875632,"twenty":-77.050014,"median":-37.033118,"eighty":115.720164,"marketCap":33248542844},{"date":"2026-05-01","current":114.357667,"twenty":-76.68,"median":-35.397875,"eighty":115.720164,"marketCap":32812988374},{"date":"2026-05-08","current":68.695502,"twenty":-76.462018,"median":-34.468285,"eighty":115.560959,"marketCap":35242166242},{"date":"2026-05-15","current":66.012693,"twenty":-76.246744,"median":-33.418249,"eighty":115.518333,"marketCap":33865831800},{"date":"2026-05-22","current":67.096218,"twenty":-76.102676,"median":-31.546239,"eighty":115.492019,"marketCap":34421701930},{"date":"2026-05-29","current":62.970154,"twenty":-75.880486,"median":-30.693232,"eighty":115.373164,"marketCap":32304948475},{"date":"2026-06-05","current":60.662245,"twenty":-75.223997,"median":-29.59006,"eighty":115.163248,"marketCap":31120945098},{"date":"2026-06-12","current":56.401824,"twenty":-74.640704,"median":-29.253094,"eighty":114.989528,"marketCap":28935263747},{"date":"2026-06-18","current":56.924083,"twenty":-74.490547,"median":-29.223519,"eighty":114.833736,"marketCap":29203193149},{"date":"2026-06-26","current":59.667569,"twenty":-74.312777,"median":-29.026044,"eighty":114.683445,"marketCap":30610656318},{"date":"2026-07-02","current":63.004827,"twenty":-74.195313,"median":-28.914242,"eighty":114.357667,"marketCap":32322736319},{"date":"2026-07-10","current":65.624791,"twenty":-74.135535,"median":-28.781271,"eighty":113.811576,"marketCap":33666830293},{"date":"2026-07-17","current":68.786518,"twenty":-74.11053,"median":-28.668245,"eighty":113.265677,"marketCap":35288859332},{"date":"2026-07-24","current":70.81271,"twenty":-74.11053,"median":-28.275697,"eighty":112.626442,"marketCap":36328336476},{"date":"2026-07-31","current":69.796363,"twenty":-73.864189,"median":-27.361812,"eighty":112.074132,"marketCap":35806930294},{"date":"2026-08-07","current":57.188468,"twenty":-73.321375,"median":-26.690447,"eighty":111.218799,"marketCap":37498879034},{"date":"2026-08-14","current":61.733374,"twenty":-72.9906,"median":-26.519964,"eighty":110.411886,"marketCap":40479005230},{"date":"2026-08-21","current":64.013629,"twenty":-72.865597,"median":-26.24637,"eighty":109.877808,"marketCap":41974184913},{"date":"2026-08-28","current":64.591063,"twenty":-72.771126,"median":-25.664335,"eighty":109.774239,"marketCap":42352812163},{"date":"2026-09-04","current":62.889975,"twenty":-72.657077,"median":-24.959227,"eighty":109.586422,"marketCap":41237396750},{"date":"2026-09-11","current":59.26931,"twenty":-72.278458,"median":-24.808073,"eighty":109.442662,"marketCap":38863301558},{"date":"2026-09-18","current":61.291195,"twenty":-72.041871,"median":-24.46985,"eighty":109.305857,"marketCap":40189065444},{"date":"2026-09-25","current":62.420051,"twenty":-71.960403,"median":-24.157208,"eighty":109.158233,"marketCap":40929264663},{"date":"2026-10-02","current":62.211967,"twenty":-71.576598,"median":-24.088675,"eighty":107.853568,"marketCap":40792822411},{"date":"2026-10-09","current":60.713761,"twenty":-67.715123,"median":-23.947641,"eighty":106.735946,"marketCap":39810438194}],"updateTime":1791823479898},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659901270","title":"康方生物双抗药物获批第三项适应证 此前击败百济神州；阿斯利康加入口服减重药“混战”：4500人Ⅲ期临床试验只对标安慰剂｜掘金创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2659901270","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659901270?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 01:22","pubTimestamp":1786555325,"startTime":"0","endTime":"0","summary":"资本眼一周行情上周（8月3日至8月7日），医药生物指数上涨4.63%，跑赢上证指数（周内上涨2.81%）1.82个百分点。创新药（BK1106）周内上涨8.66%；恒生医疗保健业指数（HSCICH）周内上涨8.09%；港股创新药ETF广发（513120）周内上涨8.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133839529518.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133839529518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK4007","LU2462157665.USD","LU0348766576.USD","LU0708994859.HKD","MDTX","BK4585","LU2237443465.HKD","IBBJ","LU0128525929.USD","LU2476274720.SGD","BK1583","LU1251922891.USD","06978","LU0417516738.SGD","LU2237443382.USD","LU1770034418.SGD","AZN","LU0310800379.SGD","BK4588","09926","LU0432979614.USD","IE00BPRC5H50.USD","LU0348784397.USD","LU1969619763.USD","MEDX","PSYK","159992","688235","ONC","LU2089984988.USD","LU0348783233.USD","LU0634319403.HKD","BMED","LU0307460666.USD","LU0289739699.SGD","AZNH","06160","BK1161","LU0109394709.USD","LU2237443622.USD","BK0239","LU0320765992.SGD","LU0588546209.SGD","LU0058720904.USD","LU2488822045.USD","IBBQ","LU2237443895.HKD","IE00B5MMRT66.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658168928","title":"【特约大V】邓声兴：美伊僵局叠加通胀隐忧，恒指或考验二万五支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2658168928","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658168928?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:02","pubTimestamp":1786503774,"startTime":"0","endTime":"0","summary":"国指跌93点或1.09%，报8528点。美伊僵局叠加通胀隐忧，恒指或考验二万五支持。此举标志着百济在“不可成药”的RAS靶点赛道上迈出关键一步，联合治疗方案的临床数据将成为中线估值的重要催化。管理层给予2026年全年总收入指引62至64亿美元，反映商业化放量持续加速。百济神州正处于核心产品放量、实体瘤管线突破及BD合作持续兑现的三重利好交汇点，中线估值重构空间值得跟进。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZjliN2ZkODRiNzhhNzU2YzM1OTEzZDg3ZjhhMTI3MDQ3NzI4ODg1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjliN2ZkODRiNzhhNzU2YzM1OTEzZDg3ZjhhMTI3MDQ3NzI4ODg1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987991","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","LU0052756011.USD","SG9999014567.USD","BK4574","LU1988902786.USD","BK4602","LU1815336760.USD","LU0342679015.USD","LU2860962120.EUR","LU0210533765.USD","EFIV","LU1633808545.USD","LU0154236417.USD","LU0557290698.USD","LU2250418816.HKD","LU2271345857.HKD","LU0109391861.USD","LU1116320901.HKD","LU1043141396.HKD","LU0061475181.USD","LU2462157665.USD","LU0149725797.USD","LU2360106780.USD","LU1202635105.USD","LU2089283258.USD","LU0354030438.USD","LU1303224171.USD","SGXZ31699556.SGD","LU0157215616.USD","LU1059921491.USD","LU1720051017.SGD","LU0310800965.SGD","LU1064131342.USD","IE00BJLML261.HKD","LU2491050071.SGD","LU1303367103.USD","LU0494093205.USD","IE0004086264.USD","LU2505996509.AUD","LU0477156953.USD","LU0792757196.USD","LU1951200564.SGD","LU1116320737.USD","GOOW","SG9999003461.SGD","LU2471134523.USD","LU0823434583.USD","IE00BDRTCR15.USD","LU0158827948.USD","IE0034235303.USD","IE0034235188.USD","LU2023250843.SGD","LU0444973449.USD","IE0034235295.USD","SG9999014542.SGD","SG9999015978.USD","LU2505996681.GBP","LU0345770308.USD","LU0588546209.SGD","LU0889566641.SGD","LU2746668461.USD","LU2213496289.HKD","LU1201861249.SGD","ILDR","LU0466842654.USD","LU1244550494.USD","LU0784385170.HKD","CQTM","LU0426412945.USD","LU1267930227.SGD","LU1046421795.USD","LU1400636657.SGD","LU1232071149.USD","LU1989764748.USD","SG9999014575.USD","LU1244550221.USD","LU0265550946.USD","LU0640476718.USD","LU1720051108.HKD","IE00BKDWB100.SGD","SG9999017495.SGD","BK1583","LU2102340556.USD","LU2430703251.USD","LU1923623000.USD","LU1301847155.USD","LU0472753341.HKD","LU0320765059.SGD","LU2746668974.SGD","LU0943347566.SGD","LU1951198990.SGD","LU2999663052.SGD","LU1674673691.USD","LU2433249047.HKD","IE00BMPRXR70.SGD","LU2125154778.USD","LU2065171402.SGD","LU1585245621.USD","LU2168564065.EUR","LU1868837300.USD","LU0648000940.SGD","LU2471134952.CNY","LU2077746001.SGD","LU0187121727.USD","IE00BFMHRM44.USD","IE00B1BXHZ80.USD","LU2097344357.USD","LU0094547139.USD","IE00B1XK9C88.USD","LU1066053197.SGD","BK1216","LU1670627923.USD","IE00BYXW3230.USD","BK4579","IE000BZT7R73.USD","IE00BBT3K403.USD","SG9999014880.SGD","LU0310800379.SGD","CMAG","LU0957791311.USD","LU1894683264.USD","LU1917777945.USD","HK0000304805.HKD","LU0823421416.USD","GOOY","VOX","688235","LU0302445910.USD","LU2462591350.SGD","LU0289960550.SGD","IE00BQXX3C00.GBP","LU0011850046.USD","BK4576","LU2592432038.USD","LU0690374615.EUR","LU2244417387.USD","LU0354030511.USD","LU0174119429.USD","LU0868494617.USD","LU1894683348.USD","LU1571399168.USD","IE0002270589.USD","LU0289739343.SGD","LU0096364046.USD","LU1770034418.SGD","LU2360032135.SGD","LU2063271972.USD","IE000F7OJYX1.SGD","LU0957808578.USD","LU2097344431.USD","LTL","LU1868836591.USD","IE00BK4W5L77.USD","LU0642271901.SGD","LU2065170008.USD","LU1366192091.USD","LU1261432733.SGD","LU2054465674.USD","SG9999018857.SGD","LU0251131958.USD","LU1823568750.SGD","LU0203347892.USD","LU0029864427.USD","LU0211331839.USD","IE00BQXX3F31.USD","XDAT","LU0106261372.USD","LU2236285917.USD","IE00BJTD4N35.SGD","LU0426417589.USD","LU0528227936.USD","SG9999014559.SGD","IE00B19Z8W00.USD","IE0004091025.USD","LU1974910355.USD","BK4533","LU0077335932.USD","LU2125909593.SGD","LU0096362180.USD","LU0127658192.USD","LU1235294995.USD","LU1989772923.USD","IE00BK4W5M84.HKD","IE00BZ1G4Q59.USD","ONC","LU0942090050.USD","LU2028103732.USD","LU0175139822.USD","LU0006306889.USD","LU0345769631.USD","LU1366333091.USD","LU0211328371.USD","LU2417539215.USD","HK0000304797.USD","LU0234572021.USD","LU0742534661.SGD","LU0708994859.HKD","BK4612","LU0496365809.HKD","LU2456880835.USD","LU0128525929.USD","LU2242650005.HKD","LU0276348264.USD","LU2087625088.SGD","LU2168564222.USD","BK1588","LU0964807845.USD","LU1066051498.USD","IE00BWXC8680.SGD","SG9999015341.SGD","IE00BSNM7G36.USD","LU0545039389.USD","GGLL","LU1670756490.USD","BK4561","LU1066051811.HKD","LU2242649171.HKD","LU1267930813.SGD","LU0323591593.USD","LU0097036916.USD","LU1642822529.SGD","LU1804176565.USD","LU1551013342.USD","BK4592","LU0820561909.HKD","LU1043141123.HKD","LU2362540622.SGD","BK1161","IE000WAW04H5.SGD","LU1316542783.SGD","LU2106854487.HKD","BK4077","LU0256863811.USD","LU2430703095.HKD","LU0267386448.USD","LU2750360641.GBP","LU0353189763.USD","IE00BLSP4452.SGD","LU0211326839.USD","LU0417517546.SGD","LU0314104364.USD","LU0985320562.USD","LU1153585028.USD","GXPC","LU2357305700.SGD","LU1674673428.USD","LU2247934214.USD","LU2362541273.HKD","LU0107464264.USD","LU0444971666.USD","BK4588","LU1670628061.USD","LU1548497426.USD","SGXZ81514606.USD","LU0048573561.USD","SG9999015358.SGD","LU1868836914.USD","BK4514","LU0348723411.USD","LU2264538146.SGD","LU2756315318.SGD","LU1201861165.SGD","LU1506573853.SGD","SGXZ99366536.SGD","IE00BKPKM429.USD","LU1430594728.SGD","LU1429558221.USD","LU0225283273.USD","METV","LU1145028129.USD","BK4532","LU0738911758.USD","LU0994945656.USD","XLC","LU1032955483.USD","LU0061474705.USD","LU1791710582.SGD","LU2087621335.USD","LU2328871848.SGD","IE0001KFT4U8.USD","IE00BMPRXQ63.HKD","GGLS","00004","BK4550","LU0234570918.USD","LU0070302665.USD","LU1496350502.SGD","LU1803068623.USD","LU2602419157.SGD","LU0208291251.USD","LU0476273544.USD","SGXZ51526630.SGD","LU0170899867.USD","06160","LU1267930730.SGD","GOOP","BK4581","LU0314106906.USD","LU2430703178.SGD","LU1914381329.SGD","LU0976567544.SGD","LU0211326755.USD","IE00B19Z3B42.SGD","LU0211327993.USD","HK0000532082.HKD","LU2404859667.USD","LU2023250330.USD","LU2168563687.JPY","LU1267930490.SGD","LU1084165304.USD","BK1534","LU2275660780.HKD","LU0056508442.USD","LU1221951046.USD","LU1718418525.SGD","LU0949170426.SGD","LU0130517989.USD","LU0345769128.USD","LU1935043536.SGD","LU0316494557.USD","LU0353189680.USD","LU1645745479.HKD","LU0138981039.USD","LU0228659784.USD","LU1969619763.USD","LU2097829019.USD","LU1989764664.SGD","LU1923622614.USD","LU0823434740.USD","LU0553294199.USD","LU2462591277.SGD","LU0345774631.USD","LU0289961442.SGD","LU0307460666.USD","KURE","BK4543","LU0198837287.USD","LU0672654240.SGD","LU2168564495.EUR","LU1839511570.USD","SG9999000418.SGD","LU2065171311.SGD","BK1500","SG9999015952.SGD","LU0784383803.USD","LU2750360997.AUD","LU1629891620.HKD","SNPE","LU2362541513.USD","LU0069063385.USD","BK4538","LU2954938101.SGD","LU0251142724.SGD","LU2491050154.USD","LU1935042215.USD","HK0000914686.HKD","LU0784384876.USD","BK4534","LU0310799852.SGD","LU0256863902.USD","LU1244550577.SGD","SG9999015945.SGD","LU0158827781.USD","LU1280957306.USD","LU0061474960.USD","IE00B19Z3581.USD","HK0000914660.USD","LU2023250504.SGD","LU2023251221.USD","LU2111349929.HKD","LU1815333072.USD","LU1551013425.SGD","IE00BDCRKT87.USD","BK4527","LU0787776722.HKD","LU0868494708.USD","LU0784385840.USD","BK4503","LU1868837136.USD","GOU","LU2092627202.USD","LU2211815571.USD","GB00B4QBRK32.GBP","LU0820562030.AUD","LU2265009873.SGD","IE00B7SZLL34.SGD","LU1989772840.SGD","LU0124676726.USD","LU1880398471.USD","LU1791710400.SGD","LU0980610538.SGD","LU2471134796.USD","LU1323610961.USD","GOOX","SG9999018865.SGD","LU0251132253.USD","LU0661504455.SGD","LU2326559502.SGD","LU0130102774.USD","LU1719994722.HKD","GOOGL","IE00BKVL7J92.USD","LU0708995401.HKD","SG9999014898.SGD","LU0345770993.USD","LU1496350171.SGD","LU1121112475.USD","IE00BQXX3D17.EUR","LU0949170772.SGD","LU0203345920.USD","LU0689626769.HKD","LU0057025933.USD","TRUC","LU0882574139.USD","IE0000B7K699.USD","HK0000819398.USD","LU1435385759.SGD","LU0128525689.USD","LU0345768740.USD","LU1066051225.USD","LU2098885051.SGD","LU1699723380.USD","IE00BD6J9T35.USD","LU1119994496.HKD","LU0648001328.SGD","LU1003077747.HKD","LU1935042991.SGD","LU1935042488.USD","LU0048584097.USD","LU0130103400.USD","LU0511384066.AUD","BK4566","IE000SO60NU8.SGD","LU0823421333.USD","WARFY","LU2381873111.SGD","LU1880398554.USD","LU2125909247.SGD","BK4585","LU0080751232.USD","SKYY","LU1251922891.USD","LU0312595415.SGD","LU2125154935.USD","LU2191332357.HKD","BK4573","SG9999014914.USD","LU0143551892.USD","FCOM","LU0683600562.USD","LU2404859741.USD","LU2089284900.SGD","LU0345768153.USD","IE00BLSP4239.USD","LU2065169927.USD","SG9999014906.USD","OGIG","LU1400636574.HKD","IE00BJTD4V19.USD","LU2491049909.HKD","BK4598","BK1601","LU0215105999.USD","LU0130518102.USD","LU0070217475.USD","SG9999015986.USD","LU0477156797.USD","LU1868836757.USD","LU2756315664.SGD","LU1400636491.USD","LU1221951129.SGD","LU0820561818.USD","LU0265550359.USD","LU0690374961.EUR","LU2420271590.USD","IE00B19Z8X17.USD","LU2092937148.SGD","IE00BHPRN162.USD","SGXZ44715902.SGD","LU1267930573.SGD","LU0828237510.HKD","LU2471134879.HKD","LU0345774391.USD","IE00BMPRXN33.USD","IE000MB6IJN5.SGD","LU1852331112.SGD","IE00B19Z9505.USD","LU2237438978.USD","GB00B4LPDJ14.GBP","LU0320765489.SGD","LU1778281490.HKD","LU1196500208.SGD","LU1935043023.USD","LU2403377893.USD","LU0689472784.USD","LU2168564149.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992720","title":"吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992720","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992720?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 19:25","pubTimestamp":1786447500,"startTime":"0","endTime":"0","summary":"8月11月，A股、港股大幅回调，医药资产受大市影响整体冲高回落，其中创新药产业链韧性凸显，批量成功收红。成份股再鼎医药领涨5.28%，权重龙头百济神州涨2.63%斩获6连阳，股价创年内新高！基金管理人评估的药ETF华宝的风险等级为R3-中风险，适宜平衡型及以上的投资者，港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型及以上的投资者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-11/doc-inimyaaf7389173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","159316","LU1719994722.HKD","LU1969619763.USD","LU0307460666.USD","LU1251922891.USD","LU2328871848.SGD","ONC","BK1500","159828","BK4139","LU1770034418.SGD","LU1303224171.USD","BK4585","688235","BK1161","06160","FLHK","BK0239","LU0828237510.HKD","KURE","LU0588546209.SGD","603087","BK1588","LU0228659784.USD","BK1583","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993724","title":"百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993724","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993724?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 16:35","pubTimestamp":1786437325,"startTime":"0","endTime":"0","summary":"8月10日，由百济神州与安进公司共同负责中国（不含港澳台地区）商业化开发的安泰适（注射用塔拉妥单抗）正式投入临床使用。截至8月10日，全国17个城市29家医疗机构已开出首批处方。据悉，塔拉妥单抗为首个且目前唯一获批的靶向DLL3和CD3的T细胞衔接器（TCE），于8月7日启动供应，首批复盖全国80个城市、超200家医疗机构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837896326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837896326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4526","BK4585","BK1583","LU1303224171.USD","BK1588","LU0828237510.HKD","06160","688235","LU1719994722.HKD","ONC","BK1500","LU0228659784.USD","LU1969619763.USD","LU1251922891.USD","LU1770034418.SGD","BK4139","BK0239","LU2328871848.SGD","BK4588","LU0307460666.USD","KURE","BK1161","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658965691?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","IE00B2B36J28.USD","LU0889565916.HKD","LU0588546209.SGD","BBH","BK4588","LU0109394709.USD","BK1500","BK4585","BK1161","LU2328871848.SGD","LU1251922891.USD","LU1770034418.SGD","LU0828237510.HKD","CANC","BK1588","LU0228659784.USD","LU1969619763.USD","PTH","06160","BK1583","IDNA","IE0009354923.USD","IE0009355771.USD","IE0002141913.USD","688235","RVMD","KCAI","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0307460666.USD","BK4526","ONC","VXUS","KURE","BK0239","LU1303224171.USD","IE00BJJMRZ35.SGD","LU1719994722.HKD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196566?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4534","BBH","IBBQ","IE00B2B36J28.USD","LU1969619763.USD","LU0122379950.USD","LU2242646821.SGD","PBE","BK4139","BK1583","BK4526","LU2112291526.USD","ONC","IBB","BK4588","LU1061106388.HKD","06160","SG9999001440.SGD","TBXU","IE0002141913.USD","BK4585","LU0588546209.SGD","LU0058720904.USD","LU2242652126.USD","LU1770034418.SGD","PJP","IE0009355771.USD","BK4599","BIB","LU0228659784.USD","LU1571399168.USD","LU1983299246.USD","BK1588","LU1023059063.AUD","BK1161","LU2089984988.USD","LU0289739699.SGD","LU0307460666.USD","LU2468319806.SGD","LU1057294990.SGD","688235","BK4566","IE00B4R5TH58.HKD","AMGN","BK4533","LU0828237510.HKD","KURE","BK1500","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965603","title":"中金：维持百济神州(06160)跑赢行业评级 目标价266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965603","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658965603?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 09:16","pubTimestamp":1786410971,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州2026年和2027年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价340元/266港币/445美元。中金主要观点如下：公司近况8月10日，百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作。该合作主要涉及两个部分：1)双方将评估并开展百济神州候选药物和Revolution的四款RAS抑制剂的联合治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06160","688235","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950149","title":"百济神州与Revolution Medicines达成临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950149?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 07:40","pubTimestamp":1786405224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","BK4585","LU0109394709.USD","ONC","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","BK4588","IE0009355771.USD","LU0889565916.HKD","CANC","IE00BJT1NW94.SGD","PTH","IDNA","RVMD","IE0009354923.USD","LU0320765992.SGD","BK4526","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950539?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IDNA","BK1588","IE0009355771.USD","LU1251922891.USD","09939","BK1574","BK4585","BK4588","06160","IE00B2B36J28.USD","BK1515","LU0228659784.USD","ONC","BK1583","BK4139","LU0307460666.USD","LU1969619763.USD","IE0009354923.USD","IE00BJJMRZ35.SGD","KURE","BD","LU0320765992.SGD","688235","LU0889565916.HKD","BBH","IE00BFTCPJ56.SGD","LU1770034418.SGD","BK1161","LU0828237510.HKD","IE0002141913.USD","RVMD","LU1719994722.HKD","BK0239","IE00B4R5TH58.HKD","BK1500","PTH","CANC","LU0588546209.SGD","LU1303224171.USD","159938","IE00BJT1NW94.SGD","LU2328871848.SGD","LU0109394709.USD","603087","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658958697","title":"瞄准“不可成药”靶点！百济神州与Revolution达成合作，布局RAS联合治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2658958697","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658958697?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 00:32","pubTimestamp":1786379520,"startTime":"0","endTime":"0","summary":"“创新药一哥”百济神州出手了。8月10日，百济神州宣布一则重磅消息：公司已经与专注于癌症药物研发的生物科技公司RevolutionMedicines达成协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与RevolutionMedicines四款临床阶段RAS(ON)抑制剂（RAS激活态抑制剂）中任意一款或多款药物的联合治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113836984610.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113836984610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","LU1969619763.USD","688235","ONC","LU0228659784.USD","LU0588546209.SGD","BK1161","KURE","BK4588","LU2328871848.SGD","BK1500","LU0828237510.HKD","BK4585","BK4139","LU1719994722.HKD","06160","BK0239","BK1588","BK1583","LU1770034418.SGD","LU0307460666.USD","BK4526","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658601016","title":"交银国际：百济神州(06160)目标价上调至276港元 维持“买入“评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658601016","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658601016?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 10:57","pubTimestamp":1786330638,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将百济神州(06160)目标价由229.2港元上调至276港元，维持\"买入\"评级。百济神州第二季泽布替尼在适应症扩大、新患渗透加深、依从性和DoT提升等因素的推动下，再次取得超预期的销售成绩，同时替雷利珠海外开启放量通道，未来与HER2双抗联用将开辟1L HER2+胃癌治疗机会。该行上调公司2026-2028年净利预测，分别至10.26亿美元、15亿美元及20.08亿美元，以反映第二季超预期的业绩表现和最新指引。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","688235","EWH","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658679842","title":"中金：百济神州“跑赢行业”维持评级 目标价升至266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658679842","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658679842?lang=zh_cn&edition=fundamental","pubTime":"2026-08-09 09:40","pubTimestamp":1786239600,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端中金发布研究报告称，综合考虑泽布替尼高增长以及费用控制，上调百济神州（06160）今年盈利预测34%至8.71亿美元，并调升2027年盈测38%至12亿美元。该行维持其“跑赢行业”评级，H股目标价升6.4%至266港元。该行表示，公司第二季业绩胜预期 ，收入同比增长30%，其中产品收入同比增长29%；GAAP预期同比增长151%至2.37亿美元，销售收入略胜于预期，超预期是由于泽布替尼高增长及费用控制良好。报告中提到，百济神州公司大幅上调主要航线，总收入航线预估约66亿至68亿美元；GAAP经营利润指引增至约10亿至11亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-09/doc-inimsnkv3665933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","688235","06160","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644339","title":"百济神州：胰腺癌中KRAS突变率约95%、MTAP缺失率约20%，重叠人群较容易识别","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644339","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644339?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:41","pubTimestamp":1786110060,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，MTAP缺失和KRAS突变均属于人类肿瘤中的高频分子事件，理论上存在较多联合机会。胰腺癌中KRAS突变率约95%、MTAP缺失率约20%，重叠人群较容易识别。肺腺癌中KRAS突变在欧美人群约30%、中国人群约10%，再叠加MTAP缺失后目标人群会明显缩小。公司会在肺癌开展探索，其他瘤种则主要根据两类突变的重叠率和早期临床信号确定优先级。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfya9837948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfya9837948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","BK4139","LU1719994722.HKD","BK1500","LU1251922891.USD","688235","LU1969619763.USD","LU2328871848.SGD","KURE","BK4526","LU0307460666.USD","LU0588546209.SGD","BK0239","ONC","BK4588","LU1303224171.USD","BK1588","BK1583","LU1770034418.SGD","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657564189","title":"中概股龙头指数盘初上涨0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657564189","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657564189?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:32","pubTimestamp":1786109554,"startTime":"0","endTime":"0","summary":"8月7日，利弗莫尔中概股龙头指数盘初上涨0.75%。成分股中，希尔威金属矿业涨8.34%，百济神州涨5.85%，禾赛涨5.38%，奇景光电涨4.87%，传奇生物涨4.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835476887.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835476887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4505","BK4139","MEDI","CANC","BK4141","MEMS","BK4526","SLVR","HIMX","06160","688235","BK4588","LU2476274308.USD","LU2778985437.USD","SVM","LEGN","LU2476274720.SGD","BK4124","SLVX","BK4585","02525","ONC","HSAI","BK4210"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644388","title":"百济神州：百悦达 目前由外部CMO供应，各环节均按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644388","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644388?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:32","pubTimestamp":1786109520,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯，百济神州在接受调研时表示，百悦达目前由外部CMO供应，各环节均按计划推进。公司预计于2026年第三季度末至第四季度初在美国正式商业化上市。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfxz3065588.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-07/doc-inimpfxz3065588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0588546209.SGD","KURE","BK4526","LU1251922891.USD","BK1161","BK4139","LU1770034418.SGD","ONC","BK0239","06160","LU0307460666.USD","BK1588","688235","LU1719994722.HKD","LU1969619763.USD","BK1500","LU2328871848.SGD","BK1583","LU1303224171.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108163796","title":"异动解读｜百济神州盘中上涨5.49%，Q2业绩大超预期叠加多家机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1108163796","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108163796?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:31","pubTimestamp":1786109500,"startTime":"0","endTime":"0","summary":"8月7日，百济神州盘中上涨5.49%，报349.09美元/股，成交额2512.75万美元。消息面上，公司Q2业绩大幅超预期，全球总收入17.05亿美元，同比增长30%；GAAP净利润2.37亿美元，同比增长151%。上半年经调整净利润8.195亿美元，同比增长111%。公司同步上调全年营收指引至449亿元至462亿元，核心产品百悦泽全球收入达12亿美元，同比增长31%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百济神州盘中上涨5.49%，Q2业绩大超预期叠加多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641869","title":"百济神州：公司在MCL已形成百悦泽、百悦达及后续联合方案的多层次布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641869","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641869?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:29","pubTimestamp":1786109340,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯，百济神州在接受调研时表示，全球MCL每年新发患者约2万人，美国亦有数千例。MANGROVE研究中百悦泽?联合利妥昔单抗相较化疗免疫方案实现HR=0.57，有望改变一线标准治疗；相比之下，阿可替尼ECHO研究是在化疗基础上加用BTK抑制剂，HR约0.73。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835474761.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835474761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","06160","BK4526","BK4585","BK4588","688235","BK1588","ONC","BK1161","LU1303224171.USD","BK1500","LU2328871848.SGD","LU1969619763.USD","BK4139","BK0239","LU1251922891.USD","LU1770034418.SGD","BK1583","LU1719994722.HKD","LU0588546209.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641539","title":"百济神州：公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641539","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641539?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:24","pubTimestamp":1786109040,"startTime":"0","endTime":"0","summary":"百济神州在接受调研时表示，公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者。具体的CEA表达阈值、PD-L1表达分层及对应疗效尚未对外披露，后续数据将提供更多信息。公司不会将该产品局限于后线，正在加快向更前线及与PD-1等方案联合推进。对于CEA与KRAS共突变等细分人群，也会根据表达重叠度和早期信号开展探索。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","LU1770034418.SGD","BK1583","BK4526","LU2328871848.SGD","06160","LU1303224171.USD","KURE","LU1251922891.USD","BK0239","BK1161","BK4588","LU1719994722.HKD","ONC","NETL","BK1500","ADC","LU1969619763.USD","BK4139","BK1588","LU0588546209.SGD","BK4080","688235","LU0307460666.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641518","title":"百济神州：GPC3x4-1BB从进入临床到启动潜在注册性2期研究仅约19个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641518","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641518?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:04","pubTimestamp":1786107840,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，GPC3x4-1BB从进入临床到启动潜在注册性2期研究仅约19个月，完成多个剂量爬坡后仍保持较好的安全性和有效性，体现了公司全球临床执行效率。公司认为研发存在“大闭环”和“小闭环”：百悦泽®从立项到全球商业成功属于大闭环，而新分子在早期临床验证安全性和有效性、并迅速进入注册性开发属于小闭环。2026年多款实体瘤产品同步完成小闭环，说明公司的靶点选择、分子质量和全球开发体系具有较强可复制性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsm4756409.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsm4756409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2328871848.SGD","BK0239","BK1500","KURE","LU1969619763.USD","BK1583","LU0588546209.SGD","BK1161","LU0307460666.USD","LU1251922891.USD","BK4139","BK4585","BK1588","BK4526","688235","06160","BK4588","LU1303224171.USD","LU1719994722.HKD","ONC","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641513","title":"百济神州：百悦泽在CLL/SLL新患中的占比已超过50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641513","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641513?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 21:04","pubTimestamp":1786107840,"startTime":"0","endTime":"0","summary":"证券日报网8月7日讯 ，百济神州在接受调研时表示，不同数据源对美国新患份额的统计口径略有差异，但百悦泽®在CLL/SLL新患中的占比已超过50%，处于较高水平。新患份额向收入转化是渐进过程：新增患者会逐年沉淀为存量患者，并随持续治疗时间延长不断贡献收入。当前平均DoT约42个月，预计将随患者累积和数据成熟继续延长，因此百悦泽®还远未达销售峰值。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsi3152709.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimnzsi3152709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","LU2328871848.SGD","KURE","688235","BK1588","LU1719994722.HKD","LU1251922891.USD","BK4585","LU0307460666.USD","BK4139","BK4526","BK0239","ONC","BK1583","BK1161","LU1770034418.SGD","LU0588546209.SGD","06160","BK4588","LU1303224171.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":173,"code":"91000000","status":"200"}]}}